Zeitschriftenartikel zum Thema „Inc Catapult“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-37 Zeitschriftenartikel für die Forschung zum Thema "Inc Catapult" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Bishko, C. J. „St James's Catapult. The Life and Times of Diego Gelmírez of Santiago de Compostela. By R. A. Fletcher. Pp. xii + 341 inc. 2 maps. Oxford: Clarendon Press, 1984. £28.“ Journal of Ecclesiastical History 36, Nr. 4 (Oktober 1985): 650–52. http://dx.doi.org/10.1017/s0022046900044067.
Der volle Inhalt der QuelleWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett et al. „Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy“. Blood 138, Supplement 1 (05.11.2021): 639. http://dx.doi.org/10.1182/blood-2021-153146.
Der volle Inhalt der QuelleBannerji, Rajat, John N. Allan, Jon E. Arnason, Jennifer R. Brown, Ranjana H. Advani, Jeffrey A. Barnes, Stephen M. Ansell et al. „Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)“. Blood 134, Supplement_1 (13.11.2019): 762. http://dx.doi.org/10.1182/blood-2019-122451.
Der volle Inhalt der QuelleVartanov, Alexander R., Stacey M. Fernandes, Winnie I. Nguy, Danielle M. Brander, Svitlana Tyekucheva, Alexandra Savell, Allison P. Jacob et al. „High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)“. Blood 134, Supplement_1 (13.11.2019): 4291. http://dx.doi.org/10.1182/blood-2019-124305.
Der volle Inhalt der QuelleSpangler, Rhys, Timo Rantalainen, Paul Gastin und Daniel Wundersitz. „Inertial Sensors are a Valid Tool to Detect and Consistently Quantify Jumping“. International Journal of Sports Medicine 39, Nr. 10 (19.07.2018): 802–8. http://dx.doi.org/10.1055/s-0044-100793.
Der volle Inhalt der QuelleNaeem, Aishath S., Winnie I. Nguy, Svitlana Tyekucheva, Stacey M. Fernandes, Vanessa Rai, Kevin Ebata, Eliana B. Gomez, Barb J. Brandhuber, Stephen M. Rothenberg und Jennifer R. Brown. „LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL“. Blood 134, Supplement_1 (13.11.2019): 478. http://dx.doi.org/10.1182/blood-2019-124362.
Der volle Inhalt der QuelleMato, Anthony R., Kavita Sail, Maryam Sarraf Yazdy, Brian T. Hill, Mazyar Shadman, Beenish S. Manzoor, Hande H. Tuncer et al. „Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies“. Blood 134, Supplement_1 (13.11.2019): 1756. http://dx.doi.org/10.1182/blood-2019-124600.
Der volle Inhalt der QuelleShadman, Mazyar, Kavita Sail, Beenish S. Manzoor, Maryam Sarraf Yazdy, Brian T. Hill, Hande H. Tuncer, John N. Allan et al. „Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study“. Blood 134, Supplement_1 (13.11.2019): 3048. http://dx.doi.org/10.1182/blood-2019-131401.
Der volle Inhalt der QuelleLampson, Benjamin L., Svitlana Tyekucheva, Conner J. Shaughnessy, Annette S. Kim und Jennifer R. Brown. „Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients“. Blood 134, Supplement_1 (13.11.2019): 1731. http://dx.doi.org/10.1182/blood-2019-127180.
Der volle Inhalt der QuelleBrown, Jennifer R., Matthew S. Davids, Julie E. Chang, Shuo Ma, Juliana M. L. Biondo, Yong Mun, Madlaina Breuleux und William G. Wierda. „Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)“. Blood 134, Supplement_1 (13.11.2019): 4320. http://dx.doi.org/10.1182/blood-2019-123665.
Der volle Inhalt der QuelleLiu, Vivian M., Romain Guièze, Daniel Rosebrock, Alexis A. Jourdain, María Hernández-Sánchez, Aina Zurita Martinez, Elisa Ten Hacken et al. „MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers“. Blood 134, Supplement_1 (13.11.2019): 1284. http://dx.doi.org/10.1182/blood-2019-131336.
Der volle Inhalt der QuelleAllan, John N., Krish Patel, Anthony R. Mato, William G. Wierda, Javier Pinilla Ibarz, Michael Y. Choi, Susan M. O'Brien et al. „Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies“. Blood 134, Supplement_1 (13.11.2019): 3041. http://dx.doi.org/10.1182/blood-2019-126286.
Der volle Inhalt der QuelleMato, Anthony R., John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Tahla Munir, Ewa Lech-Marańda et al. „Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study“. Blood 138, Supplement 1 (05.11.2021): 391. http://dx.doi.org/10.1182/blood-2021-147599.
Der volle Inhalt der QuelleFurman, Richard R., William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen et al. „Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study“. Blood 134, Supplement_1 (13.11.2019): 3039. http://dx.doi.org/10.1182/blood-2019-128706.
Der volle Inhalt der QuelleZheng, Dandan, Kavita Sail, Lindsey E. Roeker, Beenish S. Manzoor, Hande H. Tuncer, John N. Allan, Chaitra S. Ujjani et al. „Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)“. Blood 136, Supplement 1 (05.11.2020): 19–22. http://dx.doi.org/10.1182/blood-2020-134676.
Der volle Inhalt der QuelleChahal, Amandeep Kaur, Jolene Ziyuan Lim, Jing-Wen Pan und Pui Wah Kong. „Inter-Unit Consistency and Validity of 10-Hz GNSS Units in Straight-Line Sprint Running“. Sensors 22, Nr. 5 (28.02.2022): 1888. http://dx.doi.org/10.3390/s22051888.
Der volle Inhalt der QuelleHillmen, Peter, Jennifer R. Brown, John C. Byrd, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Lugui Qiu et al. „Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)“. Blood 134, Supplement_1 (13.11.2019): 4307. http://dx.doi.org/10.1182/blood-2019-124213.
Der volle Inhalt der QuelleMato, Anthony R., Ian W. Flinn, John M. Pagel, Jennifer R. Brown, Chan Y. Cheah, Catherine C. Coombs, Manish R. Patel et al. „Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor“. Blood 134, Supplement_1 (13.11.2019): 501. http://dx.doi.org/10.1182/blood-2019-127509.
Der volle Inhalt der QuelleLancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Stephen A. Strickland, Gary J. Schiller, Norbert Vey et al. „Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study“. Blood 126, Nr. 23 (03.12.2015): 2560. http://dx.doi.org/10.1182/blood.v126.23.2560.2560.
Der volle Inhalt der QuelleBachireddy, Pavan, Christina Ennis, Vinhkhang N. Nguyen, Nikolas Barkas, Sachet Shukla, Kendell Clement, Samuel Freeman et al. „Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)“. Blood 134, Supplement_1 (13.11.2019): 516. http://dx.doi.org/10.1182/blood-2019-129520.
Der volle Inhalt der QuelleTam, Constantine S., Ian W. Flinn, Alessandra Tedeschi, Emmanuelle Ferrant, Jennifer R. Brown, Tadeusz Robak, Paolo Ghia et al. „Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial“. Blood 136, Supplement 1 (05.11.2020): 24–25. http://dx.doi.org/10.1182/blood-2020-134179.
Der volle Inhalt der QuelleBrown, Jennifer R., Barbara F. Eichhorst, Paolo Ghia, Arnon P. Kater, Jianyong Li, Sudha Khurana, Mostafa Elhamy, Min Hui Wang und John F. Seymour. „A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation“. Blood 134, Supplement_1 (13.11.2019): 4318. http://dx.doi.org/10.1182/blood-2019-123057.
Der volle Inhalt der QuelleCrombie, Jennifer L., Svitlana Tyekucheva, Alexandra Savell, Karen Francoeur, Mark Choiniere, Josie Montegaard, Jacob D. Soumerai et al. „A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL“. Blood 134, Supplement_1 (13.11.2019): 1763. http://dx.doi.org/10.1182/blood-2019-127343.
Der volle Inhalt der QuelleMerryman, Reid W., Robert A. Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M. McHugh, Jennifer R. Brown et al. „Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma“. Blood 136, Supplement 1 (05.11.2020): 22–23. http://dx.doi.org/10.1182/blood-2020-140965.
Der volle Inhalt der QuelleBurke, Kathleen, Barrett Nuttall, Daniel L. Karl, Megan Callahan, Kerrin Mendler, Steven Criscione, Sergey Naumenko et al. „Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing“. Blood 138, Supplement 1 (05.11.2021): 4361. http://dx.doi.org/10.1182/blood-2021-147113.
Der volle Inhalt der QuelleDavids, Matthew S., Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai et al. „ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia“. Blood 138, Supplement 1 (05.11.2021): 2634. http://dx.doi.org/10.1182/blood-2021-153033.
Der volle Inhalt der QuelleLampson, Benjamin L., Svitlana Tyekucheva, Jennifer L. Crombie, Austin I. Kim, Reid W. Merryman, Jessica Lowney, Josie Montegaard et al. „Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)“. Blood 134, Supplement_1 (13.11.2019): 32. http://dx.doi.org/10.1182/blood-2019-127506.
Der volle Inhalt der QuelleDavids, Matthew S., Danielle M. Brander, Svitlana Tyekucheva, Chinheng Chen, James Kaminski, Josie Montegaard, Alvaro J. Alencar et al. „Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia“. Blood 138, Supplement 1 (05.11.2021): 640. http://dx.doi.org/10.1182/blood-2021-146624.
Der volle Inhalt der QuelleBall, William J. „Book Reviews : Beyond the Home Page Book Review Essay on Guides to Advanced Content Creation for the Web Introducing Microsoft FrontPage97. Kerry A. Lehto and W. Brett Polonsky. Redmond, WA: Microsoft Press, 1997. 384 pp., $24.99. Microsoft FrontPage97 Step by Step. Catapult Inc. Redmond, WA: Microsoft Press, 1997. 286 pp., $29.99. Web Scripting Secret Weapons. Scott Walker. Indianapolis, IN: Que Corp., 1997. 380 pp., $39.99. Special Edition Using JavaScript. Mark C. Reynolds. Indianapolis, IN: Que Corp., 1997. 831 pp., $49.99. VBScript by Example. Jerry Honeycutt. Indianapolis, IN: Que Corp., 1997. 355 pp., $34.99. Building VRML Worlds. Ed Tittle, Charlie Scott, Paul Wolfe, and Claire Sanders. Berkeley, CA: Osborne/McGraw Hill, 1997. 381 pp., $39.95“. Social Science Computer Review 15, Nr. 4 (Dezember 1997): 446–50. http://dx.doi.org/10.1177/089443939701500411.
Der volle Inhalt der QuelleSeymour, John F., John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard Furman et al. „Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)“. Blood 138, Supplement 1 (05.11.2021): 3721. http://dx.doi.org/10.1182/blood-2021-146228.
Der volle Inhalt der QuelleTedeschi, Alessandra, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown et al. „Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial“. Blood 138, Supplement 1 (05.11.2021): 67. http://dx.doi.org/10.1182/blood-2021-144336.
Der volle Inhalt der QuelleBrown, Jennifer R., Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, Henry Chan et al. „Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial“. Blood 136, Supplement 1 (05.11.2020): 11–12. http://dx.doi.org/10.1182/blood-2020-134280.
Der volle Inhalt der QuelleTam, Constantine S., Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti et al. „SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)“. Blood 138, Supplement 1 (05.11.2021): 396. http://dx.doi.org/10.1182/blood-2021-148457.
Der volle Inhalt der QuelleMakar, Piotr, Ana Filipa Silva, Rafael Oliveira, Marcin Janusiak, Przemysław Parus, Małgorzata Smoter und Filipe Manuel Clemente. „Assessing the agreement between a global navigation satellite system and an optical-tracking system for measuring total, high-speed running, and sprint distances in official soccer matches“. Science Progress 106, Nr. 3 (Juli 2023). http://dx.doi.org/10.1177/00368504231187501.
Der volle Inhalt der QuelleWatts, Sophie P., Martyn J. Binnie, Paul SR Goods, Matthew M. Doyle, Jamie Hewlett und Peter Peeling. „Garmin wearable device offers reliable alternative for on-water stroke rate and velocity measurement in rowing“. Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology, 18.05.2022, 175433712210993. http://dx.doi.org/10.1177/17543371221099364.
Der volle Inhalt der QuelleKenawy, A., MY Khanji, M. Chirvasa, K. Fung, A. Sojoudi, JOSE M. Paiva, N. Samy, W. Farid, TS Khalil und SE Petersen. „Application of a machine learning contouring tool for the evaluation of left ventricular strain in clinical practice“. European Heart Journal - Cardiovascular Imaging 22, Supplement_1 (01.01.2021). http://dx.doi.org/10.1093/ehjci/jeaa356.259.
Der volle Inhalt der QuelleSexton-Finck, Larissa. „Violence Reframed: Constructing Subjugated Individuals as Agents, Not Images, through Screen Narratives“. M/C Journal 23, Nr. 2 (13.05.2020). http://dx.doi.org/10.5204/mcj.1623.
Der volle Inhalt der Quelle